Obligating Health Insurers to Cover an FDA-Approved Treatment Before Pricing Is Negotiated
The ability to force an insurer to cover a newly FDA-approved treatment before pricing is set depends on the type of insurance and applicable laws. Here’s a breakdown by insurance category:
1. Private Health Insurance (Employer-Sponsored & Marketplace Plans)
✅ Possible, but challenging
- Private insurers typically determine coverage through medical policies and formularies that assess clinical effectiveness and cost.
- Even if a treatment is FDA-approved, insurers may wait for pricing negotiations before deciding coverage.
- State laws may require quicker coverage for FDA-approved treatments, especially in cancer or rare disease cases.
Options for Patients & Providers
✔ Medical Exception or Appeal – A doctor can argue medical necessity to request early coverage.
✔ State-Level Insurance Commissioner Complaint – If state law mandates coverage, regulators can intervene.
✔ Employer Pressure – If an employer sponsors the plan, they may negotiate coverage directly.2. Medicare (Traditional & Advantage Plans)
✅ Limited, but possible
- Medicare Part B (doctor-administered drugs) & Part D (prescription drugs) follow CMS reimbursement determinations, which take time after FDA approval.
- National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) influence whether Medicare pays early.
Options for Patients & Providers
✔ Compassionate Use / Expanded Access Programs – Some drugs may be available via patient assistance programs.
✔ Administrative Appeals – If a doctor proves medical necessity, Medicare may approve individual cases.
✔ Congressional or Legal Pressure – In high-profile cases, policymakers may push for faster Medicare coverage.3. Medicaid (State-Run Programs)
✅ More likely due to federal mandates
- Medicaid must cover FDA-approved drugs that participate in the Medicaid Drug Rebate Program (MDRP).
- However, states can implement prior authorization requirements before formal pricing is set.
Options for Patients & Providers
✔ Medicaid Fair Hearing Request – Patients can challenge denials through a state appeals process.
✔ Legal Challenges – In cases where a state Medicaid program delays access, legal action may force coverage.4. ACA Plans & Essential Health Benefits
✅ Depends on state mandates & plan policies
- ACA marketplace plans must cover essential health benefits, but they have discretion over which new treatments to include.
- Some states require insurers to cover new FDA-approved treatments faster than federal rules dictate.
Options for Patients & Providers
✔ State Insurance Commissioner Complaint – If state law supports coverage, regulators can intervene.
✔ Expedited Review Requests – Insurers may approve case-by-case exceptions.Bottom Line
It is possible to push an insurer to cover an FDA-approved treatment before pricing is finalized, but it depends on the type of insurance, applicable laws, and medical necessity arguments.
- Forums
- ASX - By Stock
- MSB
- Ann: Ryoncil Pricing Set and Available This Quarter
MSB
mesoblast limited
Add to My Watchlist
1.85%
!
$1.65

Ann: Ryoncil Pricing Set and Available This Quarter, page-451
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.65 |
Change
0.030(1.85%) |
Mkt cap ! $2.108B |
Open | High | Low | Value | Volume |
$1.64 | $1.67 | $1.63 | $4.884M | 2.962M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 10583 | $1.65 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.66 | 16415 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 10583 | 1.650 |
2 | 23000 | 1.645 |
10 | 116615 | 1.640 |
4 | 26536 | 1.635 |
6 | 87628 | 1.630 |
Price($) | Vol. | No. |
---|---|---|
1.660 | 16415 | 4 |
1.665 | 69454 | 8 |
1.670 | 37280 | 4 |
1.675 | 23182 | 2 |
1.680 | 37509 | 5 |
Last trade - 16.12pm 27/06/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online